Kazia Therapeutics Limited American Depositary Shares (KZIA)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Kazia Therapeutics is an oncology-focused biotechnology company with just six employees. Its lead candidate, paxalisib, is a brain-penetrant PI3K/AKT/mTOR inhibitor in Phase II/III for glioblastoma and Phase II for IDH-mutant glioma and primary CNS lymphoma. That is a high-risk, capital-intensive business. Any competitive strength would come from clinical data and regulatory exclusivity, not from scale, brands, or switching costs. The balance sheet has no debt, with a D/E of 0.00, which is a small positive. But the financial picture is fragile: as of the 2026-10-13 close, the price is $8.04 and market cap is $130.1M. FairStock shows a negative P/E of -1.07, P/B of 2.74, and ROE of -106.90%. Its Altman Z-Score is 1.07, in distress territory, and its Piotroski F-Score is 2/9. No revenue growth or profit growth figure is provided, and there is no dividend yield. The 52-week range is $4.86 to $17.40, with beta 2.15, so the shares have been volatile. Valuation rests almost entirely on pipeline hope rather than present cash flows. FairStock's Lynch category is none because there are only 0 years of filed results and 3 are needed. The growth trajectory is binary: successful trials or a partnership could transform the company, but failure, delays, or dilutive financing could impair equity value. Graham would ask for a margin of safety in assets and earnings; neither is evident. Buffett would look for durable economics; here the outcome depends on clinical events.

In plain English: Kazia Therapeutics is a small brain-cancer drug developer with six employees and no debt. The business is not yet profitable, and the provided figures show no revenue growth or profit growth. At $8.04 per share and a $130.1 million market value, the price looks expensive relative to the current lack of profits, so it depends heavily on future trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer